HighVista Strategies’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
HighVista Strategies's DNTH Position: Q3 2026 in Review
HighVista Strategies reduced its Dianthus Therapeutics (DNTH) stake by 36% in Q3 2026, selling an estimated $1.94M and leaving 32,480 shares worth $2.86M. The position accounts for 0.75% of the portfolio, ranked #39.
HighVista Strategies first reported a position in DNTH in Q3 2024 and has held it in 9 quarters since. The position peaked at $4.98M in Q2 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.
- HighVista Strategies held 32,480 shares of Dianthus Therapeutics worth $2.86M as of Q3 2026.
- HighVista Strategies sold 18,645 Dianthus Therapeutics shares in Q3 2026, an estimated $1.94M.
- Dianthus Therapeutics made up 0.75% of HighVista Strategies's portfolio in Q3 2026, its #39 holding.
- HighVista Strategies first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 9 quarters since.
- HighVista Strategies's Dianthus Therapeutics position peaked at $4.98M in Q2 2026.
- 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.
Based on HighVista Strategies's 13F filing for Q3 2026, filed 13 Nov 2026.